Sermorelin vs Tesamorelin: What the Research Compares

Research Use Only. The material discussed here is supplied strictly as a laboratory reagent and is not for human or veterinary use. Nothing on this page is medical advice, and no protocol, dose or method of administration for people or animals is described or implied.

Sermorelin and tesamorelin are two of the most frequently confused entries in the growth hormone releasing hormone (GHRH) family. Both are synthetic analogs of the same endogenous hypothalamic peptide, both act at the same receptor, and both appear in preclinical work on the somatotropic axis. Yet they differ in length, in chemical modification, in enzymatic stability and in regulatory history. This article sets the two side by side as they appear in the published literature, without any reference to human or veterinary application.

What are sermorelin and tesamorelin

Human GHRH is a 44 amino acid hypothalamic peptide that stimulates the anterior pituitary to release growth hormone. Early structure activity work established that the biological activity of the full molecule resides almost entirely in its first 29 residues. That finding produced sermorelin, which is simply GHRH(1-29) with a C-terminal amide, sometimes written as GRF(1-29)NH2. It is the shortest fragment that retains full agonist behaviour at the receptor in in vitro assays.

Tesamorelin, originally coded TH9507, takes a different approach. Instead of truncating the peptide, it keeps the full 44 residue chain and attaches a trans-3-hexenoyl group to the N-terminal tyrosine. That single acyl modification is the reason the two molecules behave differently in stability assays, because the N-terminus of GHRH is exactly where dipeptidyl peptidase-4 cleaves the native peptide.

Both compounds are agonists at the GHRH receptor, a class B G protein coupled receptor expressed on pituitary somatotrophs, which signals through Gs and cyclic AMP. In that narrow mechanistic sense they are doing the same thing. The interesting differences sit upstream of the receptor, in how long each molecule survives in a biological matrix, and downstream, in what the published research programmes actually measured. Readers new to this class may want to start with our broader growth hormone secretagogues research overview, which places GHRH analogs alongside ghrelin mimetics and oral secretagogues.

Where they sit in the research literature

The two molecules entered the literature roughly twenty five years apart and were studied with different questions in mind. Sermorelin belongs to the classical peptide chemistry era of the 1980s and 1990s, when laboratories were mapping which residues of GHRH matter and why. Barron and colleagues compared GHRH(1-29)NH2 against the longer native fragments in a controlled setting and reported comparable molar potency, which is what made the short fragment scientifically interesting in the first place. Cervini and colleagues later ran systematic alanine and lactam bridge scans across the whole 29 residue sequence, identifying which positions tolerate substitution and which abolish activity, and confirming that amphiphilicity and helical character drive receptor activation.

Tesamorelin arrived through a pharmaceutical development route rather than an academic structure activity route. The published reviews describe it as a stabilised growth hormone releasing factor analog developed specifically because the native peptide is degraded too quickly to be practical, and they document its evaluation programme in the context of the growth hormone axis.

Reported preclinical and mechanistic areas

• Receptor agonism and cAMP signalling. Both analogs have been characterised in pituitary cell preparations for their ability to trigger the GHRH receptor and raise intracellular cyclic AMP.
• Structure activity relationships. Alanine scanning, helix promoter substitution and cyclic lactam constraints across the GHRH(1-29) scaffold have identified positions 1, 3, 5, 6, 10, 11, 13, 14 and 23 as critical, while several other positions tolerate substitution or even improve in vitro potency.
• Enzymatic stability. Comparative work on N-terminal modification examines resistance to dipeptidyl peptidase-4 cleavage, the primary route by which native GHRH and unmodified GHRH(1-29) are inactivated.
• IGF-1 axis modelling. Animal and cell studies in this class typically track downstream insulin-like growth factor 1 as a readout of somatotropic axis stimulation.
• Adipose tissue biology. Literature on growth hormone axis modulation includes work on visceral adipose compartments and lipid handling in model systems.
• Analog design. Both molecules serve as reference compounds when newer GHRH analogs are benchmarked in receptor assays.

None of the above is presented as an effect in people. These are descriptions of what published preclinical and mechanistic studies examined, nothing more.

Chemistry and notes at a glance

• Sermorelin. GHRH(1-29)NH2. Twenty nine amino acids, C-terminal amide, molecular weight approximately 3358 Da. Supplied as a lyophilized white powder. Unmodified N-terminus, therefore susceptible to DPP-4 cleavage at the Ala2 position.
• Tesamorelin. Trans-3-hexenoyl-GHRH(1-44)NH2, development code TH9507. Forty four amino acids plus an N-terminal hexenoyl group, molecular weight approximately 5136 Da. Also supplied lyophilized. The acyl cap is the stability feature.
• Shared target. GHRH receptor (GHRHR), class B GPCR, Gs coupled.
• Shared handling profile. Both are hygroscopic lyophilized peptides that are markedly more stable dry than in solution.
• Key practical distinction. Chain length and N-terminal protection, which is why the two are not interchangeable reference standards in comparative assay work.

For compound specific detail, our standalone write-ups on sermorelin and tesamorelin go deeper into each molecule individually.

Why the research use only label matters

In the European Union, research peptides of this type are supplied as chemical reagents under the REACH framework. They are not medicines, they are not food supplements, and they carry no marketing authorisation for any human or veterinary purpose. That classification is what makes lawful supply possible, and it depends entirely on the material being described, sold and used as a laboratory reagent.

Regulatory and safety note. The two compounds have quite different regulatory histories. Sermorelin was formerly marketed in the United States as a prescription product and was withdrawn from that market for commercial reasons rather than safety findings. Tesamorelin received a United States Food and Drug Administration approval in November 2010 for one narrowly defined indication in a specific patient population, and it does not hold an equivalent EU-wide marketing authorisation for general use. Neither status makes either compound approved for general human use, and neither has any bearing on material supplied for laboratory work. Separately, GHRH analogs including sermorelin and tesamorelin appear on the World Anti-Doping Agency Prohibited List under section S2 covering peptide hormones and growth factors, meaning they are prohibited in sport at all times. Researchers working near competitive sport contexts should be aware of that classification.

Handling and storage for researchers

Both peptides follow the same laboratory conventions that apply across the GHRH class. Lyophilized powder should be kept sealed, protected from light and moisture, and stored frozen for long term work, typically at minus 20 degrees Celsius or colder. Vials taken from cold storage should be allowed to equilibrate to room temperature before opening, because condensation on cold glass introduces water into a hygroscopic powder and starts hydrolysis before any solvent is deliberately added.

Once reconstituted, both are considerably less stable. Solutions are normally kept refrigerated, protected from light, and used within a short working window. Repeated freeze and thaw cycling is the most common avoidable cause of loss of assay signal in peptide laboratories, so aliquoting into single use volumes before freezing is standard practice. Choice of reconstitution solvent also matters and depends on the assay, which we cover in detail in our guide to peptide storage and stability. Every batch should be accompanied by a certificate of analysis with identity and purity data before it enters comparative work.

Frequently asked questions

What is the main structural difference between sermorelin and tesamorelin?

Sermorelin is a truncated peptide, the first 29 residues of human GHRH with a C-terminal amide. Tesamorelin is the full 44 residue GHRH chain carrying a trans-3-hexenoyl group on the N-terminal tyrosine. The truncation approach preserves activity in a smaller molecule; the acylation approach protects the enzymatic cleavage site.

Do sermorelin and tesamorelin act on the same receptor?

Yes. Both are agonists at the GHRH receptor on anterior pituitary somatotrophs, a class B G protein coupled receptor that signals through Gs and cyclic AMP. Their differences lie in stability and pharmacokinetic behaviour rather than in receptor identity. This contrasts with ghrelin receptor agonists, which reach the same axis through a different receptor entirely, a distinction covered in our MK-677 vs Ipamorelin comparison.

Are sermorelin or tesamorelin approved medicines?

Neither is approved for general human use. Sermorelin was previously marketed in the United States and later withdrawn from that market. Tesamorelin holds a United States approval limited to one specific indication and population and lacks an equivalent EU-wide authorisation for general use. Material supplied by research chemical suppliers is not a medicine in any jurisdiction and is intended for laboratory work only.

Are they on the WADA Prohibited List?

Yes. GHRH analogs, including sermorelin and tesamorelin, fall under section S2 of the World Anti-Doping Agency Prohibited List covering peptide hormones, growth factors and related substances. They are prohibited in sport at all times, both in and out of competition.

Is it legal to buy sermorelin or tesamorelin for research in the EU?

Research grade peptides are supplied lawfully within the EU as chemical reagents for laboratory use, subject to REACH and to national chemical legislation. That lawful basis holds only where the material is purchased, labelled, described and used strictly for research and never presented for human or veterinary application. Buyers are responsible for compliance with the rules of their own member state and institution.

Key takeaways

• Sermorelin and tesamorelin are both synthetic GHRH analogs acting at the same class B receptor, but they solve the stability problem in opposite ways.
• Sermorelin is GHRH(1-29)NH2, the minimal fully active fragment identified through classical structure activity work.
• Tesamorelin is the full GHRH(1-44) chain with an N-terminal trans-3-hexenoyl cap that shields the dipeptidyl peptidase-4 cleavage site.
• Regulatory histories differ substantially, and neither compound is approved for general human use in the EU.
• Both are on the WADA Prohibited List under section S2.
• Storage practice is shared: dry, cold, dark, aliquoted, and used promptly once in solution.
• All published work discussed here is preclinical or mechanistic. These materials are research reagents only.

References

References sourced via PubMed.

1. Cervini LA, Donaldson CJ, Koerber SC, Vale WW, Rivier JE. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies. Journal of Medicinal Chemistry, 1998. DOI | PubMed
2. Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opinion on Investigational Drugs, 2009. DOI | PubMed
3. Barron JL, Coy DH, Millar RP. Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men. Peptides, 1985. DOI | PubMed

Research grade sermorelin and tesamorelin are available from Pure Chems as laboratory reagents with batch documentation.

Disclaimer: Research Use Only. Not for human or veterinary use, not for diagnostic or therapeutic application, and not for food or cosmetic use. All studies referenced above are preclinical or mechanistic and are described in the third person as published findings. Nothing here constitutes medical advice or a claim of any effect in people. Purchasers are responsible for handling these materials in a controlled laboratory setting and for compliance with all applicable national and EU legislation.